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Thymic senescence contributes to increased incidence of infection, cancer and auto-
immunity at senior ages. This process manifests as adipose involution. As with other 
adipose tissues, thymic adipose involution is also controlled by PPARgamma. This is 
supported by observations reporting that systemic PPARgamma activation accelerates 
thymic adipose involution. Therefore, we hypothesized that decreased PPARgamma 
activity could prevent thymic adipose involution, although it may trigger metabolic 
adverse effects. We have confirmed that both human and murine thymic sections show 
marked staining for PPARgamma at senior ages. We have also tested the thymic lobes 
of PPARgamma haplo-insufficient and null mice. Supporting our working hypothesis 
both adult PPARgamma haplo-insufficient and null mice show delayed thymic senes-
cence by thymus histology, thymocyte mouse T-cell recombination excision circle qPCR 
and peripheral blood naive T-cell ratio by flow-cytometry. Delayed senescence showed 
dose–response with respect to PPARgamma deficiency. Functional immune parameters 
were also evaluated at senior ages in PPARgamma haplo-insufficient mice (null mice do 
not reach senior ages due to metabolic adverse affects). As expected, sustained and 
elevated T-cell production conferred oral tolerance and enhanced vaccination efficiency 
in senior PPARgamma haplo-insufficient, but not in senior wild-type littermates accord-
ing to ELISA IgG measurements. Of note, humans also show increased oral intolerance 
issues and decreased protection by vaccines at senior ages. Moreover, PPARgamma 
haplo-insufficiency also exists in human known as a rare disease (FPLD3) causing met-
abolic adverse effects, similar to the mouse. When compared to age- and metabolic 
disorder-matched other patient samples (FPLD2 not affecting PPARgamma activity), 
FPLD3 patients showed increased human Trec (hTrec) values by qPCR (within healthy 
human range) suggesting delayed thymic senescence, in accordance with mouse 
results and supporting our working hypothesis. In summary, our experiments prove that 
systemic decrease of PPARgamma activity prevents thymic senescence, albeit with 
metabolic drawbacks. However, thymic tissue-specific PPARgamma antagonism would 
likely solve the issue.
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inTrODUcTiOn
The peroxisome proliferator-activated receptor (PPAR) molecu-
lar family is widely studied (1–3). These nuclear receptor proteins 
possess transcription factor activities and influence multiple cel-
lular events at the molecular level including adipocyte differentia-
tion and metabolism. Among them, PPARgamma is of particular 
interest being expressed by all adipose tissue subtypes and being 
indispensable for adipose tissue development and for the homeo-
stasis of physiological metabolism (4–7). As a consequence, in 
the mouse systemic loss of PPARgamma activity severely impairs 
glucose and lipid metabolism as characterized by others (8–10). 
In accordance, PPARgamma null mice are only viable if using 
conditional knockout strategy (11). Similar to the mouse above, 
in human PPARgamma haplo-insufficiency leads to the devel-
opment of a rare metabolic condition known as familial partial 
lipodystrophy, type 3 (FPLD3, ORPHA 79083) also characterized 
by diabetes and dyslipidemia (12–15).
In mammals, systemic PPARgamma activity may be increased 
at multiple levels. Environmental factors including exces-
sive caloric consumption or corticosteroid exposure increase 
PPARgamma activity systemically (16–18). Pharmacological 
systemic activation may be achieved through administration of 
thiazolidinediones previously used as part of oral antidiabetic 
treatment, but currently neglected due to adverse cardiovascular 
side effects (19, 20). Genetic engineering-based enhancement of 
PPARgamma activity in mouse models has also been performed 
(21). In every case, increased PPARgamma activity promotes 
adipose tissue development at multiple sites of the body.
Thymic aging is observed as adipose involution during which 
the functional thymus niche that normally supports T-cell pro-
duction is gradually lost and replaced by adipose tissue (22). The 
process starts focally in childhood then spreads and accelerates 
with puberty due to hormonal changes (23). Diminishing T-cell 
production results in decreased availability of fresh naive T-cells 
(24). Consequences include increasing incidence of infection, 
cancer and autoimmunity observed at senior ages (25, 26). Thymic 
adipose involution appears to be PPARgamma-dependent: any 
condition that systemically enhances PPARgamma activity—
either environmental, pharmacological, or genetic—accelerates 
thymic senescence or adipose involution with all its immunologi-
cal consequences (27–32). However, the opposite phenomenon 
whether systemically decreased PPARgamma activity can ame-
liorate long-term functional immune parameters has barely been 
addressed (33, 34). For this reason, we have set out to characterize 
the effect of systemic genetic PPARgamma loss of function on 
long-term immune homeostasis in both mouse and human.
MaTerials anD MeThODs
human Thymus samples
Formalin-fixed, paraffin-embedded (FFPE) human thymus 
samples from age groups 30–40, 50–60, and 70–80  years were 
obtained from the Department of Pathology (Faculty of Medicine, 
University of Pecs, Hungary.) Experiments involving human 
thymus samples were performed with the consent of the Regional 
and Local Ethics Committee of Clinical Centre, University of 
Pecs (ref. no.: 6331/2016) according to their guidelines. All 
subjects gave written informed consent in accordance with the 
Declaration of Helsinki.
human immunohistochemistry
Human thymus lobes were fixed in paraformaldehyde (4% PFA in 
PBS) then paraffin embedded. 5 µm thick sections were stained 
using immunohistochemistry (35). First, the slides were rinsed 
in heated xylene and were washed with a descending series of 
alcohol to remove paraffin. After deparaffination the slides were 
rehydrated in distilled water and antigen retrieval was performed 
by heating the slides in Target Retrieval Solution (pH 6 DAKO) 
at 97°C for 20–30 min. Subsequently slides were washed in dH2O 
and endogenous peroxidase activity was blocked with 3% H2O2 
containing TBS (pH 7.4) for 15 min. Then slides were washed three 
times with TBS containing Tween (0.05%, pH 7.4). Pre-blocking 
was carried out with 3% BSA in TBS for 20 min before overnight 
incubation with anti-PPARgamma (1:100, rabbit monoclonal 
antibody clone: C26H12 Cell Signalling Technology) primary 
antibody at 4°C. Following incubation slides were washed with 
TBS for three times then incubated with peroxidase conjugated 
secondary antibody (1:100, Polyclonal Goat Anti-Rabbit IgG, 
DAKO) for 90  min. Antibody labeling was visualized with the 
help of liquid DAB Substrate Chromogen System (DAKO). For 
nuclear counterstaining, hematoxylin staining was performed. 
Finally, slides were mounted with Faramount Aqueous Mounting 
Medium (DAKO). Histological evaluation was performed with 
the help of Panoramic MIDI digital slide scanner (3DHistech). 
Image analysis was performed using ImageJ software with IHC 
toolbox plug-in.
Mouse Breeding and Maintenance
For certain experiments, we have used wild-type and PPARgamma 
heterozygous (haplo-insufficient) or PPARgamma null (KO) mice 
of C57BL/6J genetic background. The mice were age matched, 
and both genders were used for the investigation. The design 
to generate PPARgamma KO mice was described previously 
(11). Briefly, PPARgamma+/−/Sox2Cre+ male mice were crossed 
with PPARgamma fl/fl female mice to generate heterozygous 
PPARgammafl/−/Sox2Cre− and homozygous PPAR gammaΔfl/−/
Sox2Cre+ mice, wherein the floxed allele was recombined 
resulting a null allele. Mice were housed under minimal disease 
conditions in the Laboratory Animal Core Facility of University 
of Debrecen. Animal rooms were ventilated 15  times/h with 
filtered air, mice received autoclaved pellet diet (Altromin VRF1) 
and tap water ad  libitum. The cages contained sterilized bed-
ding. Room lightning was automated with 12 h light and 12 h 
dark periods. The room temperature was 21 ± 2°C, the relative 
humidity is between 30 and 60%. Senescent animals developed 
and aged normally, without any treatment. Permission to perform 
the described animal experiments was granted to the relevant 
utilities of the University of Pecs (ref. no.: BA02/2000-46/2016). 
Permission to generate PPARgamma GM mice was granted to the 
relevant utilities of the University of Debrecen (ref. no.: TMF/82-
10/2015). Permission to perform experimental procedures with 
PPARgamma GM mice was granted to the relevant utilities of the 
University of Pecs (ref. no.: TMF/124-11/2017).
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Mouse immunofluorescence
Immunofluorescent staining was performed on 8 µm cryosec-
tions of mouse thymus lobes as described previously (35). 
Briefly, the slides were fixed in cold acetone, then dried and 
blocked to prevent non-specific staining using 5% BSA in PBS 
for 20  min before staining with fluorochrome-conjugated or 
primary antibodies: anti-EpCAM1-FITC (1:100, rat monoclo-
nal antibody clone: G8.8), anti-Ly51-PE (1:100, rat monoclonal 
antibody clone: 6C3, eBioscience), and anti-PPARgamma 
(rabbit monoclonal antibody clone: C26H12 Cell Signaling 
Technology). For secondary antibody, Alexa-555 conjugated 
a-rabbit goat IgG (1:200, Life Technologies) was used. In certain 
cases, DAPI (Life Technologies) nuclear counterstain was also 
applied. Sections were analyzed using a Nikon Eclipse Ti-U 
microscope equipped with a CCD camera (Andor Zyla 5.5) and 
NIS-Elements software. The medulla/cortex ratio was calculated 
using ImageJ software.
Mouse Flow cytometry
Thymocyte subsets and T-cell subpopulations in blood were 
investigated by flow-cytometry as published by others (36, 37). 
Thymocytes and PBMC were isolated from mice and labeled 
with fluorophore-conjugated antibodies in PBS-BSA (5% BSA 
diluted in PBS). In every case, 100,000 cells were stained for 
measurement. Incubation with antibodies was performed at 
4°C for 60 min followed by a washing step. FACSCanto II flow-
cytometer and FACSDiva software (Becton Dickinson) were 
used for analysis. In every case, 10,000 events (parent R1 mor-
phological lymphocyte gate) were recorded by flow-cytometry. 
For thymocyte subset measurement, Alexa-647 conjugated anti-
mouse CD4 (clone: YTS 191) and FITC-conjugated antimouse 
CD8 (clone: IBL 3/25) antibodies were used (both produced in 
the Department of Immunology and Biotechnology, University 
of Pecs, Hungary). For peripheral blood T-cell subpopulation 
analysis, Pacific Blue-conjugated antimouse CD3 (clone: 17A2), 
PerCP-conjugated antimouse CD4 (clone: GK1.5), APC/Cy7-
conjugated antimouse CD8 (clone: YTS156.7.7), PE-conjugated 
antimouse CD44 (clone: IM7), APC-conjugated antimouse 
CD62L (clone: MEL-14) (all purchased form BioLegend), and 
FITC-conjugated antimouse CD19 (clone: 1D3, produced by the 
Department of Immunology and Biotechnology, University of 
Pecs, Hungary) were used.
T-cell recombination excision circle 
(Trec) Measurement by Digital qPcr in 
Mouse and human
T-cell recombination excision circle by-products of gene-
rearrangement in fresh naive T-cells were also assessed. We 
performed mouse Trec (mTrec) digital qPCR using mouse and 
human Trec (hTrec) digital qPCR using human samples by 
adapting methods published by others (38). Briefly, DNA was 
isolated from mouse thymocytes using the NucleoSpin Tissue kit 
(Macherey-Nagel) according to the manufacturer’s instruction. 
For human, peripheral-blood samples were processed using 
the DNA Blood Mini kit (Qiagen) following the manufacturer’s 
guides. Absolute copy numbers were measured by digital PCR 
on the QuantStudio 3D Digital PCR platform (ThermoFisher) 
using 30 ng DNA per sample. Taqman primers/probes and digital 
qPCR reagents were also purchased from ThermoFisher and used 
as suggested. For age-matched range of healthy human hTrec val-
ues, refer to the work of Lynch et al. (38). Permission to perform 
the described animal experiments was granted to the relevant 
utilities of the University of Pecs (ref. no.: BA02/2000-46/2016). 
Experiments involving human blood samples were performed 
with the consent of the Regional and Local Ethics Committee of 
Clinical Centre, University or Pecs (ref. no.: 6439/2016) accord-
ing to their guidelines.
Oral Tolerance induction in Mouse
Induction and evaluation of oral tolerance was performed 
as described by others (39–41). Briefly, both wild-type and 
PPARgamma haplo-insufficient mice received 5 mg/ml ovalbu-
min (OVA, Sigma-Aldrich) in drinking water for seven days. 
On day 7, mice were challenged with an intraperitoneal injec-
tion of 5 µg ovalbumin in 200 µl of 1:1 of PBS:complete Freund 
adjuvant. On day 14, mice received an intraperitoneal injection 
of 5  µg ovalbumin in 200  µl of 1:1 of PBS:incomplete Freund 
adjuvant. Serum was collected on day 21 and anti-OVA IgG 
antibodies were measured by ELISA. Briefly, 96-well Microtest 
Plates (Sarstedt) were coated with OVA and blocked with BSA. 
Then plates were incubated with serial dilutions of mouse serum 
samples (1:100–1:3,200). The antibody content was visualized 
with the help of HRP-conjugated antimouse immunoglobulin 
antibody (rabbit polyclonal, Dako). Optical density was meas-
ured at 492  nm with iEMS Reader MF equipment (Thermo 
Labsystems).
influenza Vaccination in Mouse
The efficiency of influenza vaccination was investigated as 
described elsewhere (42). Briefly, both wild-type and PPARgamma 
haplo-insufficient mice were injected intramuscular once with 
0.1  ml human seasonal influenza vaccine cocktail (3Fluart) to 
mimic human vaccination at 9 months of age. In order to imitate 
human exposure pattern serum antibody IgG titer against H1N1 
A/California/7/2009 strain (part of 3Fluart) was measured by 
ELISA three months after initial single vaccination at 12 months 
of age. For detection, ELISA plates were coated with 0.05  μg 
HA protein of influenza strain A (Recombinant subtype H1N1 
A/California/7/2009 His Tag, Life Technologies). Then plates 
were incubated with serial dilutions of mouse serum samples 
(1:5–1:1,600). The antibody content was visualized with the help 
of HRP conjugated a-mouse immunoglobulin antibody (rabbit 
polyclonal, Dako). Optical density was measured at 492 nm with 
iEMS Reader MF equipment (Thermo Labsystems).
statistical analysis
All experiments were performed at least on three occasions, 
representative experiments are shown. Measures were obtained 
in triplicates, data are presented as mean and +SD as error bars. 
Graphpad Prism software was used for statistical analysis. Two-
tailed Student’s t-test was applied. Significant differences are 
shown by asterisks (ns for not significant, * for p ≤ 0.05, ** for 
p ≤ 0.01, *** for p ≤ 0.001).
FigUre 1 | PPARgamma expression in the adult thymus. Human formalin-fixed, paraffin-embedded (FFPE) thymic sections were analyzed for PPARgamma 
expression by immunohistochemistry in age groups of 20–30 years called young adult (a), 50–60 years called middle-aged (B), and 70–80 years called senior  
(c). Brown color reaction (DAB) shows PPARgamma expression. Blue color (hematoxylin) shows nuclear counter-stain and defines total cellular areas. The ratio of 
PPARgamma-expressing cellular areas and total cellular areas is also shown for the different age groups (D). Immunofluorescent staining is also shown for mouse  
at 1 month of age called young adult and at 15 months of age called senior (e,F). Green color shows epithelial cells (anti-EpCAM1-FITC), red color shows 
preadipocytes (anti-PPARgamma primary AB with Alexa-555 secondary AB) and blue color defines nuclei (DAPI counter-stain). Note arrowheads pointing at 
double-staining (EpCAM-1+/PPARgamma+) cells (F). Both stainings show expected patterns: EpCAM-1 staining presents cell surface markers, while PPARgamma-
staining shows nuclear localization (observed in magenta color due to overlap with DAPI nuclear counterstain on Figure 1F). For exact numerical data, refer to 
Supplementary Material. Significant differences are shown by asterisks (ns for not significant, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
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resUlTs
PPargamma Distorts the ratio of Thymic 
epithelial compartments with age
Previously reported mouse results showed increasing 
PPARgamma expression with age in the thymic epithelial com-
partments, accompanied by thymic adipose involution. We have 
set out to prove human relevance of previous mouse findings and 
test whether PPARgamma activity influences the ratio of thymic 
epithelial compartments.
PPARgamma Expression Increases in the Adult 
Thymus with Age
Human FFPE thymic sections were analyzed for their 
PPARgamma expression in several adult age groups from young 
through middle-aged to senior (Figures  1A–D). Our results 
indicate that PPARgamma expression significantly and progres-
sively increases with age (Figures 1A–C). Of note, total cellular 
areas shrink at senior ages in both human (Figure 1C) and mouse 
(Figure  1F). As a result the ratio of PPARgamma-expressing 
cellular areas shows relative increase with age (Figure  1D). 
Immunofluorescent staining of mouse thymic cryosections at 
15 months of age (Figure 1F) provides visual support for thymic 
epithelial to adipose transdifferentiation in harmony with the 
working hypothesis of cellular transdifferentiation. A portion 
of stromal cells shows dual staining for epithelial identity and 
adipose differentiation, a hallmark of thymic adipose involution. 
This phenomenon is not observed at young adult age (Figure 1E).
PPARgamma Skews the Ratio of Epithelial 
Compartments with Age
Mouse thymic cryosections were differentially stained for 
medullary and cortical epithelial compartments at several ages 
FigUre 2 | Ratio of epithelial compartments in the adult thymus. Mouse thymic cryosections were stained differentially for medullary (anti-EpCAM1-FITC++, 
anti-Ly51-PE−) and cortical (anti-Ly51-PE++, anti-EpCAM1-FITC+) epithelial compartments. Wild-type thymus is shown at 1 month (a) and 8 months of age  
(B). PPARgamma heterozygous (c) and PPARgamma KO (D) animals are shown at 8 months of age. The ratio of medullary and cortical epithelial compartment is 
also shown (e) for both ages and genetic backgrounds. For exact numerical data, refer to Supplementary Material. Significant differences are shown by asterisks  
(ns for not significant, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
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and using various genetic backgrounds (Figures  2A–D). Our 
results show that in the wild-type setting the medullary epi-
thelial compartment significantly shrinks with age as reported 
previously (31). This, however, is not observed in PPARgamma 
deficient settings. Loss of PPARgamma activity shows protection 
in a progressive manner presenting dose–response (Figure 2E). 
PPARgamma deficiency efficiently and significantly prevents 
the erosion of the medullary epithelial compartment, otherwise 
prone to shrink with senescence.
PPargamma affects Thymic T-cell 
Production and Peripheral Blood T-cell 
Distribution with age
We have observed changes in thymus architecture in response 
to PPARgamma status. Consequently, we were interested in 
whether morphological changes alter thymus function: naive 
T-cell production. Going beyond, we were eager to see if sus-
tained influence of PPARgamma status on thymocyte function is 
also reflected in the peripheral blood.
PPARgamma Disturbs Thymic T-Cell Output with Age
Age-related changes in thymocyte levels of mTrec (DNA loop 
by-product of mouse T-cell receptor gene rearrangement) were 
evaluated in wild-type and PPARgamma deficient settings using 
digital qPCR (Figure  3A). Our results indicate slight (though 
not significant) decrease of mTrec and hence fresh-naive T-cell 
output with age in thymocytes of wild-type mice. PPARgamma 
deficiency significantly and progressively counteracts the process 
also showing dose-responsive increase of thymocyte mTrec 
levels. In further analyses, the percent distribution of thymocyte 
FigUre 4 | T-cell subpopulations in adult peripheral blood. Peripheral blood 
T-cell subpopulations were evaluated by flow-cytometry at 12 months of age 
in wild-type and PPARgamma heterozygous animals (KO animals decease by 
this age). Percent distribution of T-cells (CD3+), helper T-cells (CD3+, CD4+), 
and cytotoxic T-cells (CD3+, CD8+) is shown by (a). Also, the percent 
distribution of naive T-cells (CD3+, CD44−, CD62L+) and memory T-cells 
(CD3+, CD44+, CD62L+/−) was evaluated within the CD3-gate of T-cells  
(B). Further analysis of memory T-cell subpopulation shows percent 
distribution of effector memory T-cells (CD3+, CD44+, CD62L−) and central 
memory T-cells (CD3+, CD44+, CD62L+) within the CD3-gate of T-cells  
(c). For the measurement of every sample, 100,000 cells were stained and 
10,000 events (parent R1 morphological lymphocyte gate) were recorded  
by flow-cytometry. For exact cell numbers, refer to Supplementary Material. 
Significant differences are shown by asterisks (ns for not significant, * for 
p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
FigUre 3 | Thymocyte development in the adult thymus. Changes in level 
of mouse T-cell recombination excision circles (mTrecs) was evaluated by 
Taqman digital qPCR in wild-type, PPARgamma heterozygous, and 
PPARgamma KO thymocytes (a). The columns represent mTrec values 
measured at 8 months divided by those measured at 1 month for every 
strain. The ratio of thymocyte subpopulations was assessed by 
flow-cytometry at 8 months of age in wild-type, PPARgamma 
heterozygous and PPARgamma KO animals (B). Double negative (CD4−, 
CD8−), double positive (CD4+, CD8+), and single positive (CD4+ or CD8+) 
subpopulations are shown. For the measurement of every sample, 
100,000 cells were stained and 10,000 events (parent R1 morphological 
lymphocyte gate) were recorded by flow-cytometry. For exact cell 
numbers, refer to Supplementary Material. Significant differences are 
shown by asterisks (ns for not significant, * for p ≤ 0.05, ** for p ≤ 0.01, 
*** for p ≤ 0.001).
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subpopulations was assessed using flow-cytometry in wild-type 
and PPARgamma deficient mice (Figure  3B). All thymocyte 
subpopulations showed near identical distribution pattern with 
all genetic backgrounds. Taken together, PPARgamma deficiency 
progressively enhances thymocyte development in adult age, but 
without skewing the distribution of thymocyte subpopulations or 
their differentiation preference.
PPARgamma Influences T-Cell Subpopulation 
Distribution in Adult Peripheral Blood
Peripheral blood T-cell subpopulations were evaluated by flow-
cytometry at 12  months of age in wild-type and PPARgamma 
deficient animals. Our results do not show differences in the 
percent distribution of the major T-cell groups of helper T-cells 
and cytotoxic T-cells (Figure 4A) within the CD3-gate of T-cells. 
However, the evaluation of naive T-cell and memory T-cell ratio 
reveals significant effect of PPARgamma deficiency (Figure 4B). 
There is significant increase of naive T-cells in the peripheral 
blood of PPARgamma deficient animals compared to wild-type 
animals, conversely and significantly decreasing the memory 
T-cell pool within the CD3-gate of T-cells. Deeper analysis of 
the memory T-cell pool reveals it is the mobile effector memory 
T-cell subpopulation that shows significant decrease and not 
central memory T-cells (Figure  4C) within the CD3-gate of 
T-cells. Sustained and prolonged naive T-cell production due to 
PPARgamma deficiency in the thymus as suggested by mTrec 
values above apparently affects peripheral blood T-cell subpopu-
lations as shown here.
FigUre 5 | Functional immunological experiments in adult hosts. Oral 
tolerance induction capacity to ovalbumin (OVA) was assayed in wild-type 
and PPARgamma heterozygous animals at 12 months of age. Animals 
received OVA by either drinking water, i.p. injection, both or neither. 
OVA-specific IgG titers were evaluated 3 weeks later by ELISA method  
(a). The presented figure was obtained using 1:400 dilution of serum.  
Mean ELISA OD values are shown for each study group. Human seasonal 
influenza vaccine (3Fluart) was injected (0.1 ml, 1×, i.m.) into wild-type and 
PPARgamma heterozygous animals at 9 months of age. Serum IgG titers 
specific to a vaccine component (H1N1 A/California/7/2009 strain) were 
tested 3 months later by ELISA method (B). The presented figure was 
obtained using 1:50 dilution of serum. Maximal ELISA OD values are shown 
for each study group. For exact numerical data, refer to Supplementary 
Material. Significant differences are shown by asterisks (ns for not significant, 
* for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001).
FigUre 6 | Thymus function in adult FPLD patients. Level of human T-cell 
recombination excision circle (hTrec) was measured by Taqman digital qPCR 
in peripheral blood leukocytes of age-matched and disease-matched rare 
disease patients with FPLD2 condition (lipodystrophy due to LMNA 
deficiency) and FPLD3 condition (lipodystrophy due to PPARgamma 
deficiency) (Figure 6). Patient sample numbers were n = 3 for FPLD2 and 
n = 5 for FPLD3. For exact numerical data, refer to Supplementary Material. 
For age-matched (approx. 50 years of age) range of healthy human hTrec 
values, refer to the work of Lynch et al. (38). Accordingly, the lower limit of 
healthy human hTrec threshold (approximaterly 200 copies/μg DNA) is 
represented by dotted line.
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Functional immunological consequence 
and human relevance
Having seen the far-reaching influence of PPARgamma status 
on thymus architecture, thymus function and peripheral blood 
T-cell composition with age, we have set out to test whether these 
changes have functional immunological relevance. If so, it would 
be also of high interest to test if our comprehensive mouse results 
have human relevance.
PPARgamma Modulates Immune Regulation  
and Immune Response
We have tested the capacity to mount oral tolerance to the foreign 
protein OVA in wild-type and PPARgamma deficient aged adult 
mice by measuring OVA-specific IgG titers following oral and/
or intraperitoneal OVA challenge (Figure 5A). As reported by 
others, age impairs oral tolerance in wild-type animals (40, 41). 
As a consequence, there is only moderate, insufficient decrease 
of OVA-specific IgG titers in case of parallel oral OVA admin-
istration and i.p. OVA-injection in senior animals. However, 
PPARgamma deficiency rescues oral tolerance in the same 
experimental setting despite age, profoundly and significantly 
decreasing OVA-specific IgG titers (Figure 5A). Consequently, 
naive T-cell dependent immune regulation (oral tolerance) 
remains efficient in PPARgamma heterozygous animals despite 
their age.
The capacity to mount immune reaction to foreign influenza 
antigens was also tested as human seasonal influenza vaccine was 
injected into aged adult wild-type and PPARgamma deficient 
animals. Subsequent analysis of serum IgG titers specific to a vac-
cine component showed elevated protective antibody production 
(maximal ELISA OD values) in PPARgamma deficient animals, 
but not in their wild-type littermates (Figure 5B). This tendency 
is not significant because of individual variation observed due 
to the applied human vaccination protocol being inferior to 
standard mouse immunization protocol. Nevertheless, naive 
T-cell dependent immune response proves to be efficient in aged, 
PPARgamma heterozygous animals.
Human Evidence of PPARgamma Deficiency 
Preventing Thymic Senescence
Genetic PPARgamma deficiency is a rare, but existing condition 
in human called FPLD3 (15). It leads to a metabolic phenotype 
called lipodystrophy, similar to the mouse (11–15). Other rare 
human conditions not affecting PPARgamma can also lead 
to lipodystrophy (12–15). In case of FPLD2 lamin mutations 
trigger similar metabolic changes (14). Peripheral blood hTrec 
(DNA loop by-product of human T-cell receptor gene rearrange-
ment) levels were measured using digital qPCR in age-matched 
patients with FPLD2 condition and FPLD3 condition (Figure 6). 
As expected and in perfect harmony with previous mouse 
thymocyte results elevated mean hTrec levels were detected in 
FPLD3 samples compared to FPLD2 samples. The tendency is 
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not significant due to individual variation within the patient 
groups. Unfortunately, current patient sample numbers cannot 
be increased due to the extremely rare nature of these conditions 
(FPLD2 or ORPHA 2348 has prevalence of ≤1/1,000,000 and 
FPLD3 or ORPHA 79083 also has prevalence of ≤1/1,000,000) 
(14, 15). For age-matched range of healthy human hTrec values, 
refer to the work of Lynch et  al. (38). Lower limit of healthy 
human hTrec threshold (approx. 200 copies/μg DNA) is not 
reached by FPLD2 (lamin) patient samples, but this is rescued 
in FPLD3 (PPARgamma) patients despite being age and disease 
matched.
DiscUssiOn
PPargamma Drives Thymic epithelial to 
adipose Trans-Differentiation with age
It has been previously suggested based on direct fate-mapping 
experiments that with senescence thymic adipose tissue develops 
from the thymic stromal or epithelial compartment (28). Based 
on indirect evidence others have also supported this concept 
(29). In further support, we here present visual evidence of 
epithelial to adipose transdifferentiation in the mouse. This is 
indicated by the presence by EpCAM-1/PPARgamma double-
positive cells shown by histology (Figure 1D). These cells still 
express cell surface markers of their fading thymic epithelial 
identity (EpCAM-1), but already show early signs of the novel 
adipocyte differentiation program in their nuclei (PPARgamma). 
The fact that such double positive cells show rather scattered and 
not uniform staining pattern at a given time point may provide 
explanation for gradual thymic adipose involution observed 
during senescence.
PPargamma impairs naive T-cell 
Production with age
Thymus histology data show that the medullary compartment 
is rescued from age-related shrinking in case of PPARgamma 
deficiency (Figures 2A–D). Extended survival of this stromal 
niche ensures permissive environment for sustained thymus 
function: naive T-cell production. This is indicated by elevated 
mTrec values showing direct correlation with PPARgamma defi-
ciency (Figure 3A). Of extreme importance and highlighting 
human relevance, peripheral blood leukocyte hTrec values from 
adult FPLD3 patients (with genetic PPARgamma deficiency) 
also exceed adult FPLD2 patient values (with unrelated genetic 
background) despite being age-matched and disease-matched 
(lipodystrophy, diabetes) (Figure 6). Of note, such metabolic 
disorders are known to impair thymus function indicated 
by decreased hTrec values as reported by others (43, 44). For 
exactly, this reason have we used disease-matched controls 
(FPLD2 vs. FPLD3) to show enhanced thymus function with 
PPARgamma deficiency despite metabolic disorders. Unlike 
lower than physiological hTrec values measured in FPLD2 
(lamin) patients, those measured in FPLD3 (PPARgamma) 
patients are within healthy human physiological range 
(Figure 6). Since both mTrec and hTrec DNA loops originate 
from gene rearrangement during thymocte development this 
is direct evidence of sustained T-cell development indicating 
intact thymic niche in PPARgamma deficient animal models 
and human patients (38). Of note, the distribution of thymo-
cyte subpopulations shows identical pattern irrespective of 
PPARgamma status proving that sustained, enhanced thymo-
cyte development does not skew differentiation preference, but 
rather enhances fresh, naive T-cell production of all thymocyte 
subtypes uniformly (Figure 3B). Finally, since sustained thymic 
naive T-cell production is not restricted to a given time-point, 
but rather represents a continuous trend, the peripheral blood 
naive T-cell population shows cumulative differences as it is 
rescued from age-driven shrinking, against the memory T-cell 
population—more specifically against the effector memory 
T-cell pool (Figures 4B,C).
PPargamma hampers T-Dependent 
immune regulation and immunity with 
age
Oral consumption of foreign T-depended antigen normally 
initiates immune tolerance inhibiting any eliminative immune 
response (e.g., serum IgG), despite parallel immunization in 
young adult individuals with appropriate naive T-cell supply. 
Unfortunately, the phenomenon is disrupted at senior age due 
to the lacking naive T-cell pool in the Peyer’s patches of the 
gut (40, 41, 45) This loss of oral tolerance (impaired immune 
regulation) is a possible link to increasing food intolerance 
prevalence observed in the aging adult population (46–49). 
However, the phenomenon may be rescued by PPARgamma 
deficiency despite age providing evidence that sustained T-cell 
production is necessary for efficient oral (immune) tolerance 
(Figure 5A).
Senescence-triggered decrease of naive T-cell output also 
impairs T-dependent immunity. An example in the senior 
human population is decreased protection from seasonal flu 
strains despite annual vaccination campaigns (50–52). The 
phenomenon has well established animal models (53–55). 
This is caused by low levels of neutralizing antibody titers due 
to lacking naive T-cells necessary during T-B cooperation to 
mount adequate innate immune response against T-dependent 
antigens of the vaccine. This, however, is not the case with 
PPARgamma deficiency (Figure  5B). Single intramuscular 
vaccination against seasonal flu (mimicking human vaccination 
campaign) resulted in higher maximal antibody production 
three months later (a typical delay in human exposure). This 
confirms that the cause of decreased vaccination efficiency in 
the senior population is impaired T-dependent immunity due 
to thymic senescence.
In our experiments, we have focused on the decline of 
T-dependent immunity since the thymus shows early and dra-
matic signs of senescence during adipose involution. This, how-
ever, is not the case for the B-cell compartment for which aging 
has been reported to occur later and in a more gradual fashion, 
lacking such profound histological changes (56).
PPARgamma is an enigmatic transcription factor showing 
unique expression pattern in both time and space throughout the 
body (57). PPARgamma affects both hemopoietic and stromal 
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compartments during development and aging. Further dissec-
tion would require to perform, e.g., bone-marrow transplanta-
tion experiments between control and PPARgamma deficient 
animals. However, PPARgamma KO animals develop severe 
metabolic disorders that hamper such experiments, especially at 
elevated ages.
limitations and Perspectives
We here present the long-term thymus- and T-dependent 
immunity-preserving effect of systemic (genetic) loss of 
PPARgamma function as observed in PPARgamma deficient 
mouse models and in a human rare disease (FPLD3). In 
both cases, there are severe metabolic drawbacks (diabetes, 
dyslipidemia etc.) due to systemically lacking PPARgamma 
activity. However, alternative, thymus tissue-restricted sup-
pression of PPARgamma activity would likely solve the issue. 
Of note, as reported previously, overexpression of Wnt4 
glycolipoproteins by thymic epithelial cells can efficiently 
counteract PPARgamma (31). Also, Wnt4 was described to 
travel in extracellular vesicles including exosomes and affect 
thymocyte differentiation (58, 59). Hence, it is conceivable 
that thymic epithelium-derived, enriched exosomes would 
efficiently home to the thymus and deliver their Wnt4 cargo 
locally even when administered systemically. This would, in 
theory, allow for the natural, tissue-specific, protein-mediated 
maintenance of thymic epithelial identity and prevent thymic 
senescence from developing.
Although tissue senescence is ultimately inevitable, there 
are conditions that accelerate thymic senescence including cer-
tain viral infections, intoxications, irradiation, chemotherapy, 
etc. Outcomes include increased incidence of infection, cancer 
and autoimmune disorder. In any case, the identification of 
molecular level targets for potential intervention is highly 
desired. Therefore, molecular level insight into immune senes-
cence has medical, economical, and personal relevance, all at 
once.
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